Risedronate in the treatment of Murine Chagas' disease

Boumediene Bouzahzah, Linda A. Jelicks, Stephen A. Morris, Louis M. Weiss, Herbert B. Tanowitz

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.

Original languageEnglish (US)
Pages (from-to)184-187
Number of pages4
JournalParasitology research
Issue number3
StatePublished - Jun 2005

ASJC Scopus subject areas

  • Parasitology
  • General Veterinary
  • Insect Science
  • Infectious Diseases


Dive into the research topics of 'Risedronate in the treatment of Murine Chagas' disease'. Together they form a unique fingerprint.

Cite this